MCL1 and hematologic disorder: Clinical evaluation of MCL-1 inhibitors for hematological malignancies is currently underway, with a major clinical objective to determine a safe therapeutic window for this class of inhibitors, in accordance with physiological roles of Mcl-1 [184].